The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Valeant Pharmaceuticals International Inc

NYSE: VRX
Last

(U.S.) $8.60

Today's change+0.09 +1.06%
Updated April 24 4:02 PM EDT. Delayed by at least 15 minutes.
 

Valeant Pharmaceuticals International Inc

NYSE: VRX
Last

(U.S.) $8.60

Today's change+0.09 +1.06%
Updated April 24 4:02 PM EDT. Delayed by at least 15 minutes.

Valeant Pharmaceuticals International Inc up (U.S.)$0.09

Valeant Pharmaceuticals International Inc closed up Monday by (U.S.)$0.09 or 1.06% to (U.S.)$8.60. Over the last five days, shares have lost 9.28% and sit 3.48% above their 52-week low. This security has underperformed the S&P 500 by 89.61% during the last year.

Key company metrics

  • Open(U.S.) $8.56
  • Previous close(U.S.) $8.51
  • High(U.S.) $8.78
  • Low(U.S.) $8.31
  • Bid / Ask-- / --
  • YTD % change-40.77%
  • Volume15,671,069
  • Average volume (10-day)13,031,141
  • Average volume (1-month)19,447,148
  • Average volume (3-month)18,000,476
  • 52-week range(U.S.) $8.31 to (U.S.) $38.50
  • Beta-0.10
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forward2.20×
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$6.92
Updated April 24 4:02 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-24.89%

Valeant Pharmaceuticals International Inc has a net profit margin of -24.89%. Besides being negative, it is also below the industry average and implies that this company is not effective at turning revenues into bottom line profit.
Company Books

S&P TSX0.63%Sector:Industry:
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2016Q3/2016Q2/2016Q1/2016
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedDec 31, 201612/31/2016Sep 30, 201609/30/2016Jun 30, 201606/30/2016Mar 31, 201603/31/2016
Revenue2,4032,4802,4202,372
Total other revenue--------
Total revenue2,4032,4802,4202,372
Gross profit1,7371,8221,7621,742
Total cost of revenue665658658630
Total operating expense2,2523,3432,3402,305
Selling / general / administrative665661672813
Research & development93101124103
Depreciation / amortization284807888695
Interest expense (income), net operating--------
Unusual expense (income)4531,1154442
Other operating expenses, total931-4523
Operating income150-8638166
Interest income (expense), net non-operating-467-470-473-427
Gain (loss) on sale of assets--------
Other--------
Income before tax-360-1,332-377-366
Income after tax-512-1,219-304-373
Income tax, total152-113-737
Net income-515-1,218-302-374
Total adjustments to net income--------
Net income before extra. items-515-1,218-302-374
Minority interest-312-1
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-515-1,218-302-374
Inc. avail. to common incl. extra. items-515-1,218-302-374
Diluted net income-515-1,218-302-374
Dilution adjustment----0--
Diluted weighted average shares350350345345
Diluted EPS excluding extraordinary itemsvalue per share-1.47-3.49-0.88-1.08
Dividends per sharevalue per share--0.000.000.00
Diluted normalized EPSvalue per share-0.64-1.38-0.78-1.00